1
|
Monsrud A, Avadhani V, Mosunjac M, Krishnamurti U. PD-L1 Expression is Associated with Poorer Survival in Anal Squamous Cell Carcinoma: Analysis from an Urban Public Hospital. Am J Clin Pathol 2020. [DOI: 10.1093/ajcp/aqaa161.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction/Objective
Upregulation of programmed death-ligand 1 (PD-L1), an immunoregulatory protein is associated with adverse outcome in several malignancies. Very few studies have evaluated PD-L1 expression in anal squamous cell carcinoma. This study aims to correlate PD-L1 expression with clinicopathologic factors and clinical outcomes.
Methods
After IRB approval, formalin-fixed, paraffin embedded sections of 58 cases of anal invasive squamous cell carcinoma from 2010–2018 were immunostained for PD-L1 (Dako 22C3 monoclonal antibody). Of these, 51 cases could be evaluated for PD-L1 expression. Greater than 1% of tumor cells with partial or complete membrane staining was interpreted as PD-L1 positive (PD-L1 +). PD-L1 expression was correlated with age, sex, stage, HIV status, HIV viral load, CD4 count, disease progression, and cancer specific survival. Kaplan-Meier curves for overall survival (OS) were plotted and compared using the log rank test. Cox regression analysis was performed to identify significant prognostic factors (Two-tailed p< 0.05 was considered statistically significant).
Results
Of the 51 cases evaluated, PD-L1 was positive in 18/51 (35%) and negative in 33/51 (65%) cases. The median cancer specific survival (MCSS) was lower in PD-L1 positive cases (22 months) compared with PD-L1 negative cases (48 months), p=0.008. The number of cancer specific deaths was higher in the PD-L1 + group (50% vs. 30%), but not statistically significant (p= 0.23). Other factors that were not significantly different between the two groups were age, sex, stage, HIV status, HIV viral load, and number of patients with cancer progression. Patients with positive PD-L1 had worse OS (5yr OS: 41% for PD-L1 positive vs 64% for PD-L1 negative; p=0.02). On multivariate analysis, PD-L1 positive status remained statistically significant for worse OS, HR = 6.5 (95% CI 1.2–33.9), p=0.027.
Conclusion
The median cancer specific survival and 5-yr OS is significantly lower in the PD-L1 positive group. PD-L1 positive status is associated with a worse prognosis independent of stage, HIV status, HIV viral load, and CD4 count. The study highlights the potential of PD-L1 targeted therapy in better management of anal squamous cell carcinoma.
Collapse
Affiliation(s)
- A Monsrud
- Pathology, Emory University, Atlanta, Georgia, UNITED STATES
| | - V Avadhani
- Pathology, Emory University, Atlanta, Georgia, UNITED STATES
| | - M Mosunjac
- Pathology, Emory University, Atlanta, Georgia, UNITED STATES
| | - U Krishnamurti
- Pathology, Emory University, Atlanta, Georgia, UNITED STATES
| |
Collapse
|
2
|
Dababneh M, Birdsong G, Mosunjac M, Krishnamurti U. HPV 16/18/45 Are Not The Most Frequent Genotypes In Women Of African-American Descent: Analysis In Cervical Pap Smears Of Women In An Inner-City Hospital. Am J Clin Pathol 2020. [DOI: 10.1093/ajcp/aqaa161.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction/Objective
HPV-driven cervical cancer is one of the leading causes of cancer-related deaths in women. More African American (AA) and Hispanic women are reported to get HPV-associated cervical cancer than women of other ethnicities, possibly because of decreased access to testing or treatment. High variation has been reported in the attribution of specific HPV genotypes among various ethnicities and races. Here we report the distribution of high- risk (HR) HPV genotypes in an inner-city hospital that primarily serves an AA population.
Methods
Genotyping of HR-HPV+ (encompassing 14 genotypes) cervical cytology specimens commenced in October 2018 at our institution. The presence of genotypes 16, and 18/45 (combined) are separately reported; 11 other high-risk genotypes are pooled in cases that were HR-HPV+. The HR-HPV and HPV genotyping assays were performed by the Aptima method (Hologic, Inc.) Distribution of HPV genotypes by the Bethesda diagnostic categories for the period October 2018 to March 31, 2020 was evaluated.
Results
A total of 13,160 cervical Pap smear cases were screened, and 10,060 cases were tested for HR-HPV. HR- HPV positive rate was 14% (1412/10060), of which 78% were in African Americans (AA), 14% in Hispanics, 4% in Caucasians, and 4% in others. HPV genotyping results were available for 1136 of the HR-HPV + cases. The cytology diagnoses (n) with their corresponding HPV genotyping results and distribution (HPV16, HPV18/45, and other HPVs), respectively, are as follows: NILM (270), 3.7%, 5.9%, and 90.4%; ASCUS (415), 8.2%, 6.8%, and 84.8%; LSIL (247), 8.1%, 13.0%, and 78.1%; ASCH (100), 18.0%, 13.0%, and 67.0%; HSIL (74), 20.3%, 14.9%, and 60.8%; AGC (30), 6.66%, 3.33%, and 90.0%, respectively. Co-infection with both HPV 16 and HPV 18/45 was seen in only 0.7% of all cases (4.0% of HSIL).
Conclusion
Overall, the HR-HPV positive rate was 14.0%. HPV 16/18/45 positivity accounts for ~18% of all HR-HPV positive cases. HPV 16/18/45 positivity is lowest in Pap-negative cases (9.6%) and highest in cases with HSIL (39.2%). Co-infection with HPV 16 as well as 18/45 is rare. This study highlights that in women of AA descent, it is not HPV genotypes 16/18/45 but other HPV genotypes that are more frequent.
Collapse
Affiliation(s)
- M Dababneh
- Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, UNITED STATES
| | - G Birdsong
- Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, UNITED STATES
| | - M Mosunjac
- Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, UNITED STATES
| | - U Krishnamurti
- Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, UNITED STATES
| |
Collapse
|
3
|
Lee R, Deleveaux A, Mosunjac M, Lee S, Chen Y, Matthews R, Del Priore G. Characterization of care before endometrial cancer diagnosis at an urban safety net hospital for assessment of potential screening intervention. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
4
|
Abstract
Angiomyolipoma is a very rare benign renal tumor. This paper presents the autopsy finding of an angiomyolipoma in the transplanted kidney.
Collapse
Affiliation(s)
- M Mosunjac
- Department of Pathology, University of Zagreb Medical School, Croatia, Yugoslavia
| | | | | | | |
Collapse
|
5
|
Guo X, Koff JL, Moffitt AB, Cinar M, Ramachandiran S, Chen Z, Switchenko JM, Mosunjac M, Neill SG, Mann KP, Bagirov M, Du Y, Natkunam Y, Khoury HJ, Rossi MR, Harris W, Flowers CR, Lossos IS, Boise LH, Dave SS, Kowalski J, Bernal-Mizrachi L. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. Oncogene 2017; 36:4224-4232. [PMID: 28368397 DOI: 10.1038/onc.2017.90] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2016] [Revised: 02/15/2017] [Accepted: 02/26/2017] [Indexed: 12/15/2022]
Abstract
Diffuse large B-cell lymphoma (DLBCL) has been categorized into two molecular subtypes that have prognostic significance, namely germinal center B-cell like (GCB) and activated B-cell like (ABC). Although ABC-DLBCL has been associated with NF-κB activation, the relationships between activation of specific NF-κB signals and DLBCL phenotype remain unclear. Application of novel gene expression classifiers identified two new DLBCL categories characterized by selective p100 (NF-κB2) and p105 (NF-κB1) signaling. Interestingly, our molecular studies showed that p105 signaling is predominantly associated with GCB subtype and histone mutations. Conversely, most tumors with p100 signaling displayed ABC phenotype and harbored ABC-associated mutations in genes such as MYD88 and PIM1. In vitro, MYD88 L265P mutation promoted p100 signaling through TAK1/IKKα and GSK3/Fbxw7a pathways, suggesting a novel role for this protein as an upstream regulator of p100. p100 signaling was engaged during activation of normal B cells, suggesting p100's role in ABC phenotype development. Additionally, silencing p100 in ABC-DLBCL cells resulted in a GCB-like phenotype, with suppression of Blimp, IRF4 and XBP1 and upregulation of BCL6, whereas introduction of p52 or p100 into GC cells resulted in differentiation toward an ABC-like phenotype. Together, these findings identify specific roles for p100 and p105 signaling in defining DLBCL molecular subtypes and posit MYD88/p100 signaling as a regulator for B-cell activation.
Collapse
Affiliation(s)
- X Guo
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - J L Koff
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - A B Moffitt
- Duke Institute for Genome Sciences and Policy, Department of Medicine, Duke University, Durham, NC, USA
| | - M Cinar
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - S Ramachandiran
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Z Chen
- Department of Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - J M Switchenko
- Department of Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - M Mosunjac
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
| | - S G Neill
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
| | - K P Mann
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
| | - M Bagirov
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
| | - Y Du
- Department of Pharmacology, Emory University, Atlanta, GA, USA
| | - Y Natkunam
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - H J Khoury
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - M R Rossi
- Department of Radiation Oncology, Emory University, Atlanta, GA, USA
| | - W Harris
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - C R Flowers
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - I S Lossos
- Division of Hematology Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - L H Boise
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - S S Dave
- Duke Institute for Genome Sciences and Policy, Department of Medicine, Duke University, Durham, NC, USA
| | - J Kowalski
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.,Department of Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - L Bernal-Mizrachi
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
| |
Collapse
|
6
|
Lund MJ, Mosunjac M, Davis KM, Gabram SGA, Rizzo M, Okoli J, Bumpers HL, Zelnak A, Hearn S, Styblo T, O'Regan RM. Abstract P2-09-13: 21 Gene Recurrence Scores: Racial Differences in Testing, Scores, Treatment, and Outcome. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-09-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: African American (AA) women experience higher breast cancer mortality than white (W) women, partly attributable to their development of poor prognosis tumors and differences in access and treatment. However mortality differences persist among estrogen receptor positive (ER+) breast cancers, despite similar stage and treatment. The 21-gene recurrence score (RS) assay (Oncotype DX) is used to determine optimal individualized treatment in patients with ER+, node negative (N-) breast cancer. Results are reported on a continuum and also trichotomized into 3 RS groups: low(0-18), intermediate(19-31) and high(>31), the latter most likely benefitting from chemotherapy, achieving less benefit with hormonal therapy, and exhibiting lower ER levels (intrinsically categorized as luminal B cancers). We investigated differences between AA and W women in RS, treatment, and outcome.
METHODS: Tumor registry data from three Atlanta hospitals identified female invasive breast cancers of AA or W descent diagnosed during 2005-2009. Additional medical record abstraction obtained information on RS, treatment, and outcome. Statistical analyses employed chi-square, fisher exact, t-tests, and multivariate logistic regression. RESULTS: Of 1987 cases (AA=1110, W=877), 773 were identified as Stage I-II, ER+N-, thus eligible for RS testing [AA=350(45.3%), W=423 (54.7%), P<0.0001]; 170 (22.2%) of those received RS testing [AA=47(13.4%), W=123(29.1%), P<0.0001]. Patients distributed into the following risk groups: Low=91, Medium=63, High=16; mean(median) RS=19.0(17.0), range=0-69.
Neither mean RS (AA=20.4, W=18.5, p=0.287) nor risk groups (Low=51.1% vs 54.5%, Medium=34.0% vs 38.2%, and High=14.9% vs 7.3% for AA and W women respectively, p=0.333) significantly differed by race. However, AA women were more likely than W women to be diagnosed under age 50 (40.4% vs 23.5%, p=0.036) with higher prevalence of tumors of larger size (Mean = 2.0 cm vs 1.6cm, p=0.038) and Grade III (23.4% vs 8.1%, p=0.0.026), and stage II disease (38.3%% vs 23.6%, p=0.057). Only grade and tumor size were associated with RS in multivariate analyses.
After median follow-up of 20 months (range 1-55), 5 women recurred (2AA, 3W); 2 low, 2 intermediate, and 1 high risk. Chemotherapy was received by 40 women (Low=7, Medium=19, High=14) and did not differ by race (AA=31.9%, W=20.3%, p=0.156). Hormonal therapy was received by 80.5% of W and 63.8% AA women (p=0.027). DISCUSSION: AA women were less likely than W women to be diagnosed with ER+N-breast cancers and to receive RS testing if diagnosed. Of those tested, RS scores did not significantly differ by race. However, AA women tended to have poorer prognostic factors. Our data suggest that testing guidelines are not equivalently applied, that selection bias in testing could be attenuating any real racial differences in RS, and that disparate outcomes could partly be explained by treatment differences, treatment effectiveness e.g. endocrine agent metabolism, compliance, as well as differences in prognostic factors; all areas requiring future exploration.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-13.
Collapse
Affiliation(s)
- MJ Lund
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - M Mosunjac
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - KM Davis
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - SGA Gabram
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - M Rizzo
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - J Okoli
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - HL Bumpers
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - A Zelnak
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - S Hearn
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - T Styblo
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| | - RM. O'Regan
- Winship Cancer Institute, Emory Universisty School of Medicine, Atlanta, GA; Morehouse University School of Medicine, Atlanta, GA; Grady Cancer Center of Excellence, Atlanta, GA
| |
Collapse
|
7
|
Mosunjac M, Park J, Strauss A, Birdsong G, Du V, Rizzo M, Okoli J, Bumpers H, Gabram-Mendola S. Waiting Time for Breast Conserving Surgery Patients in a Public and a Private University Affiliated Hospital in Atlanta. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The time it takes for a patient to undergo the entire breast cancer pathway treatment varies for diverse patient populations in different health care settings. In this study we analyzed delay in breast cancer treatment (DBCT) for a defined population of breast cancer patients. All of the patients had identical cancer care trajectories of breast-conserving therapy (BCT) for infiltrating ductal carcinoma (IDC) or ductal carcinoma in situ (DCIS), followed by neo-adjuvant therapy in two different hospital settings; including a University-based inner-city hospital and a University-affiliated private practice hospital.Materials and Methods: A retrospective chart review of 214 patients treated from 2004 to 2008 was conducted. Five consecutive diagnostic and treatment events in a total of four time intervals (see Figure 1 below) were defined and correlated with demographic factors such as age, race, marital status, distance traveled to visit, insurance status type, and hospital type. Non-parametric Wilcoxon Rank-Sum test was used for statistical analysis.Results: The mean ages of the patients in both hospitals were similar (59.2 yrs public hospital vs. 61.9 yrs private hospital). Patients treated in the public hospital experienced greater DBCT compared to patients who were treated in the private institution (125 vs. 88 days, p < 0.001). Overall, the largest delay was the time period from diagnostic core biopsy to surgery (50 days). The only time interval that showed greater delay for African-American (AA) women compared to Caucasian women was time from final pathology diagnosis to medical oncology evaluations (26 vs. 33 days, p=0.036). Patients who were married or insured experienced less DBCT compared to patients who were not (80 vs. 117 days and 83.3 vs.167 days respectively, p < 0.001). Medicaid patients had shorter wait times in the public compared to in the private hospital (136 vs. 153 days, ns). Patients who experienced less than 90 days of delay to undergo the entire treatment traveled an average 27.3 miles (sd=76.6) for their hospital visit, while patients who experienced greater than 90 days of delay to undergo the same treatment traveled an average 14.2 miles (sd=19.9) for their hospital visit.Discussion: Differences in DBCT are multi-factorial and arise from system-based issues that vary among hospital settings along with demographic factors such as marital status and race that are independent of the hospital setting. More effective scheduling for surgical treatment and follow up appointments may reduce the wait time. In order to significantly shorten DBCT further, prospective studies are needed to evaluate the intricate connection of psychosocial and system barriers to breast cancer treatment.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3070.
Collapse
Affiliation(s)
| | | | | | | | | | | | - J. Okoli
- 5 Morehouse School of Medicine, GA,
| | | | | |
Collapse
|
8
|
Sundstrom JB, Martinson DE, Mosunjac M, Bostik P, McMullan LK, Donahoe RM, Gravanis MB, Ansari AA. Norepinephrine enhances adhesion of HIV-1-infected leukocytes to cardiac microvascular endothelial cells. Exp Biol Med (Maywood) 2003; 228:730-40. [PMID: 12773706 DOI: 10.1177/153537020322800613] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Recent reports have indicated that norepinephrine (NE) enhances HIV replication in infected monocytes and promotes increased expression of select matrix metalloproteinases associated with dilated cardiomyopathy (DCM) in vitro in co-cultures of HIV-infected leukocytes and human cardiac microvascular endothelial cells (HMVEC-C). The influence of NE on HIV infection and leukocyte-endothelial interactions suggests a pathogenic role in AIDS-related cardiovascular disease. This study examined the effects of norepinephrine (NE) and HIV-1 infection on leukocyte adhesion to HMVEC-C. Both flow and static conditions were examined and the expression of selected adhesion molecules and cytokines were monitored in parallel. NE pretreatment resulted in a detectable, dose-dependent increase of leukocyte-endothelial adhesion (LEA) with both HIV-1-infected and -uninfected peripheral blood mononuclear cells (PBMCs) relative to media controls after 48 hr in co-culture with HMVEC-C in vitro. However, the combination of NE plus HIV infection resulted in a significant (P < 0.0001) 18-fold increase in LEA over uninfected media controls. Increased levels in both cell-associated and -soluble ICAM-1 and E-Selectin but not VCAM-1 correlated with increased LEA and with HIV-1 infection or NE pretreatment. Blocking antibodies specific for ICAM-1 or E-Selectin inhibited HIV-NE-induced LEA. These data suggest a model in which NE primes HIV-1-infected leukocytes for enhanced adhesion and localization in HMVEC-C where they can initiate and participate in vascular injury associated with AIDS-related cardiomyopathy.
Collapse
Affiliation(s)
- J B Sundstrom
- Department of Pathology, Emory University, Atlanta, Georgia 30322, USA.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Sundstrom JB, Mosunjac M, Martinson DE, Bostik P, Donahoe RM, Gravanis MB, Ansari AA. Effects of norepinephrine, HIV type 1 infection, and leukocyte interactions with endothelial cells on the expression of matrix metalloproteinases. AIDS Res Hum Retroviruses 2001; 17:1605-14. [PMID: 11779348 DOI: 10.1089/088922201753342013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The expression of matrix metalloproteinases (MMPs) associated with AIDS-related cardiomypathies and cocaine abuse was examined in an in vitro coculture model. Human peripheral blood mononuclear cells (PBMCs), HIV infected or uninfected, were placed in coculture with primary human cardiac microvascular endothelial cells (HMVEC-C) in the presence or absence of the cocaine-inducible catecholamine norepinephrine (NE). Culture supernatants were assayed for MMP-1, -2, -3, -7, -9, and -13, and for tissue inhibitor of metalloproteinase 1 (TIMP-1) and TIMP-2, by enzyme-linked immunosorbent assay. Low levels of constitutively expressed MMP-1 and -2 were detected in individual cultures of HMVEC-C and PBMCs. NE did not induce MMP or TIMP expression by HMVEC-C and caused modest increases (3- to 4-fold) in MMP-1 and -2 by uninfected PBMCs. Increased levels of NE-induced MMP-1 (5-fold) and MMP -2 (15-fold) were detected in cocultures of HMVEC-C and uninfected PBMCs. HIV infection enhanced MMP-1 (46-fold) and MMP-2 (48-fold) and active MMP-7 (33-fold) and MMP-9 (50-fold) by PBMCs. Coculture of HIV-infected PBMCs with HMVEC-C increased MMP-1 (110-fold) and MMP-2 (307-fold) but not active MMP-7 and -9. The combination of NE, HIV infection, and coculture increased MMP-1 (126-fold) and MMP-2 (467-fold), and active MMP-7 (65-fold) and MMP-9 (75-fold). MMP-3 or-13 was not detected in any of the treatment groups and TIMP-1 and -2 appeared inversely proportional to the observed levels of MMPs. These results suggest that HIV infection, NE, and leukocyte endothelial interactions demonstrate separate and overlapping cooperative effects on the regulation of expression of TIMPs and MMPs associated with AIDS-related cardiomyopathies.
Collapse
Affiliation(s)
- J B Sundstrom
- Department of Laboratory Medicine, Winship Cancer Institute, Room B4337, Emory University School of Medicine, Atlanta, GA 30322, USA.
| | | | | | | | | | | | | |
Collapse
|
10
|
Lankford KV, Mosunjac M, Hillyer CD. Effects of UVB radiation on cytokine generation, cell adhesion molecules, and cell activation markers in T-lymphocytes and peripheral blood HPCs. Transfusion 2000; 40:361-7. [PMID: 10738040 DOI: 10.1046/j.1537-2995.2000.40030361.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Immunomodulatory effects of UV light have increasingly become a focus in transfusion medicine, BMT and transplantation immunology. In the transplant setting, the use of UVB radiation may reduce or abolish T-cell activation without compromising either bone marrow (BM) engraftment or graft-versus-leukemia effect. In this study, BM and apheresis-derived peripheral blood HPCs were used to investigate the effects of UVB on colony-forming ability, CD34+ cell viability, and growth potential, as well as on the secretion of MNC cytokines and the expression of cell surface markers and adhesion molecules. STUDY DESIGN AND METHODS After UVB radiation, enriched populations of T cells and antigen-presenting cells (APCs) were treated with PHA, and the MNC response was measured, as was colony-forming ability. CD34+ cells were quantified and their growth potential was determined in culture. Next, T-cell activation status, cell adhesion molecule and cell surface activation marker expression, and cytokine profiles were evaluated, and cytokine mRNA was quantitated. Parallel studies were done in unirradiated control cell populations. RESULTS Low-dose (10 mJ/cm(2)) UVB mitigates MNC proliferative responses by 94 percent while maintaining 60 and 80 percent of colony-forming ability in peripheral blood HPC and BM preparations, respectively, and >50 percent of colony-forming ability in CD34+ cell-enriched samples. Low-dose UVB radiation also significantly reduces T-cell production of TNFalpha, TNFalpha mRNA, TNFbeta, IL-2, and IL-6 and downregulates T-cell expression of CD28, CD25, CD69, and intercellular adhesion molecule 1. CONCLUSION These findings have shown that a "window" of low-dose UVB radiation (10 mJ/cm(2)) exists, at which BM- and peripheral blood-derived MNC proliferation is inactivated, while the HPCs are relatively spared. UVB light selectively affects T cells, while APCs are resistant to low doses of UVB. UVB radiation also alters the expression of some cell surface markers and cytokines that are important in T-cell activation pathways. Reduction of T-cell activation without cytocidal effect may allow UVB radiation to become an immunomodulating agent in BM or HPC transplantation.
Collapse
Affiliation(s)
- K V Lankford
- Departments of Pathology and Laboratory Medicine and of Medicine, and the Winship Cancer Center, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | | | |
Collapse
|
11
|
Marcikić M, Kraus Z, Dmitrović B, Mosunjac M, Marusić A. [Civilian massacre near Podravska Slatina, 3 September 1991]. Lijec Vjesn 1991; 113:208-10. [PMID: 1762479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Twenty one civilians, 5 women and 16 men, were found dead in their doorways and yards after Serbian terrorists attacked the village of Cetekovac on 3 September 1991. The age of the decedents ranged from 18 to 91 years. The oldest victims were women (aged 63, 68, 72, 86 and 91). The wounds found on 19 decedents were characteristic of the long-range gunshot wounds, with projectiles fired mostly from the back or/and the side of the body. The autopsy of one decedent (J. B.) revealed that he died from two stabbing wounds and that those were the only wounds inflicted to the body. The body of the decedent (M. S.) was heavily carbonized so that the cause of the death or even whether he was alive when his body was set on fire could not be estimated.
Collapse
Affiliation(s)
- M Marcikić
- Glavni Stozer Saniteta Republike Hrvatske
| | | | | | | | | |
Collapse
|
12
|
Mosunjac M, Danilović Z, Mosunjac M, Manojlohić S, Seivert S, Cviko A. [Comparison of clinical and pathomorphologic diagnosis in autopsies of primary microcellular bronchial carcinoma]. Plucne Bolesti 1991; 43:13-5. [PMID: 1662817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Correlation between clinical and pathomorphological diagnosis in 117 autopsy cases with primary bronchial oat cell carcinoma has been done. In more than 1/3 of all cases clinicians did not recognise primary bronchial neoplasm, in 1/4 they made the proper diagnosis of oat cell carcinoma, and in rest of the cases clinical diagnosis was "Carcinoma bronchi", without proper histological type, or they only made the doubt about bronchial carcinoma. Such diversity between clinical and pathomorphological diagnosis could be explained by specific biological behaviour, rather nonspecific clinical signs, and most of all, an increasing rate of this carcinoma in younger patients. In conclusion, it is necessary to point out the importance of interdisciplinary approach, in the first place pathologists and clinicians, what might certainly contribute to the quality of work for both.
Collapse
Affiliation(s)
- M Mosunjac
- Zavod za patologiju Medicinskog fakulteta Sveucilista u Zagrebu
| | | | | | | | | | | |
Collapse
|